# Beneficial Bacteria Treatment for Autism

> **NCT02504554** · PHASE1,PHASE2 · COMPLETED · sponsor: **Arizona State University** · enrollment: 18 (actual)

## Conditions studied

- Gastrointestinal Problems
- Autism Spectrum Disorders

## Interventions

- **DRUG:** oral Vancomycin
- **DRUG:** MoviPrep
- **DRUG:** Prilosec
- **BIOLOGICAL:** human fecal material; processed, frozen administered orally
- **BIOLOGICAL:** human fecal material; processed, frozen; administered orally and rectally

## Key facts

- **NCT ID:** NCT02504554
- **Lead sponsor:** Arizona State University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-09-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02504554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02504554, "Beneficial Bacteria Treatment for Autism". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT02504554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*